Biotech investors often chase early-stage companies in the hope that a single breakthrough trial will deliver massive returns ...

GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape ...

If you are wondering whether Gilead Sciences stock still offers value at current levels, it helps to start with what the recent share price is signalling and how that lines up with fundamentals.

Gilead Sciences is downgraded from "Strong Buy" to "Buy" as technical momentum has softened despite robust fundamentals. Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion ...

US pharma major Gilead Sciences (Nasdaq: GILD) says The New England Journal of Medicine has published full Phase III data for Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) in ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings ...

Gilead Sciences has bolted another asset onto the virology engine that powers the company, paying (PDF) Health Hope Pharma $10 million upfront for global rights to a candidate in a limited set of ...

When Fierce caught up with Paul Stoffels, M.D., back in June 2022, the Johnson & Johnson veteran was enthusiastic about his recent return to Galapagos—a company he had founded—and the Belgian ...

Gilead Sciences offers innovative drugs and boasts a 45,000% return since IPO, highlighting substantial growth. Investing in Gilead is accessible via brokerage accounts, using simple steps to buy ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...